These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19175875)

  • 21. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
    Laharie D; Seneschal J; Schaeverbeke T; Doutre MS; Longy-Boursier M; Pellegrin JL; Chabrun E; Villars S; Zerbib F; de Lédinghen V
    J Hepatol; 2010 Dec; 53(6):1035-40. PubMed ID: 20801541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
    Gopal DV; Rabkin JM; Berk BS; Corless CL; Chou S; Olyaei A; Orloff SL; Rosen HR
    Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).
    Degos F; Perez P; Roche B; Mahmoudi A; Asselineau J; Voitot H; Bedossa P;
    J Hepatol; 2010 Dec; 53(6):1013-21. PubMed ID: 20850886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [ANRS HC 02 RIBAVIC: histo-pathological impact].
    Pol S
    Gastroenterol Clin Biol; 2009 Mar; 33 Suppl 2():S106-9. PubMed ID: 19375037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
    Castells L; Esteban JI; Bilbao I; Vargas V; Allende H; Ribera E; Piron M; Sauleda S; Len O; Pahissa A; Esteban R; Guardia J; Margarit C
    Antivir Ther; 2006; 11(8):1061-70. PubMed ID: 17302376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
    Aguilar Marucco D; Gonzalez de Requena D; Bonora S; Tettoni C; Bonasso M; De Blasi T; D'Avolio A; Sciandra M; Siccardi M; Baietto L; Trentini L; Sinicco A; Cariti G; Di Perri G
    J Antimicrob Chemother; 2008 Apr; 61(4):919-24. PubMed ID: 18238889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography.
    Posthouwer D; Mauser-Bunschoten EP; Fischer K; VAN Erpecum KJ; DE Knegt RJ
    J Thromb Haemost; 2007 Jan; 5(1):25-30. PubMed ID: 17239163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
    Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
    J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
    Berends MA; Snoek J; de Jong EM; Van Krieken JH; de Knegt RJ; van Oijen MG; van de Kerkhof PC; Drenth JP
    Liver Int; 2007 Jun; 27(5):639-45. PubMed ID: 17498249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
    Poynard T; de Ledinghen V; Zarski JP; Stanciu C; Munteanu M; Vergniol J; France J; Trifan A; Le Naour G; Vaillant JC; Ratziu V; Charlotte F;
    J Hepatol; 2012 Mar; 56(3):541-8. PubMed ID: 21889468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.
    Nguyen-Khac E; Chatelain D; Tramier B; Decrombecque C; Robert B; Joly JP; Brevet M; Grignon P; Lion S; Le Page L; Dupas JL
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1188-98. PubMed ID: 18705692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
    Poynard T; McHutchison J; Manns M; Myers RP; Albrecht J
    Hepatology; 2003 Aug; 38(2):481-92. PubMed ID: 12883493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment for recurrent hepatitis C virus infection after liver transplantation.
    Balbi E; Leal CR; Pacheco-Moreira LF; Pousa FS; Covelo MC; Gonzalez AC; Oliveira PV; Agoglia L; Roma J; Cariús LP; Enne M
    Transplant Proc; 2009 Apr; 41(3):891-4. PubMed ID: 19376381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
    Maylin S; Laouénan C; Martinot-Peignoux M; Panhard X; Lapalus M; Nicolas-Chanoine MH; Bedossa P; Asselah T; Marcellin P
    J Clin Virol; 2012 Jan; 53(1):43-7. PubMed ID: 22099210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.
    Picciotto FP; Tritto G; Lanza AG; Addario L; De Luca M; Di Costanzo GG; Lampasi F; Tartaglione MT; Marsilia GM; Calise F; Cuomo O; Ascione A
    J Hepatol; 2007 Mar; 46(3):459-65. PubMed ID: 17196700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.